HLS Therapeutics Inc.

TSX:HLS.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.76 -2.51%

-$0.11 today

Market cap
$116.32M
Beta
0.85
P/E (TTM)
-9.6
EPS (TTM)
-$0.33
52W Low $0.00High $5.77

Volume 0.04M

Average 0.01M

HLS.TO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

HLS Therapeutics Inc.TSX: HLS.TO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $5.45M rose 1.6% year over year, ahead of the -0.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at -13.6% a year.

Context

  • Depreciation & amortization amounted to 39.3% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.6% holds above the trailing-twelve-month pace of -0.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.45M-1.8% QoQ
Last fiscal yearDec 2025
$22.2M-2.3% YoY
LTMMar 2026
$21.99M-0.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.6%——
1 year-2.3%——
3-year CAGR-13.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
22.2M USD
Year-over-year change
-2.3%
4-year CAGR
-7.5%

Depreciation & Amortization vs competitors

How HLS.TO compares with its peers on the latest reported figures

  • HLS.TO's LTM Mar 2026 depreciation & amortization of $21.99M is the 3rd highest of the 7 companies compared; the peer median is $4.56M.
  • Its year-over-year change of -0.8% is the 2nd highest of 7, against a peer median of -17.5%.
  • Depreciation & amortization amounts to 39.4% of revenue for HLS.TO, versus a peer median of 6.2%.
HLS.TO Competitors Peer median
Depreciation & Amortization for HLS.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHCBausch Health Companies Inc.LTM Jun 2026$1.17B -5.6%-4.7%10.8%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$194.29M -20.8%-2.4%6.2%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$21.99M -0.8%-13.6%39.4%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$4.96M -16.3%-0.3%11.8%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$4.16M +116.2%+31.6%4.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$528K -18.8%-38.4%1.1%
NERVMinerva Neurosciences, Inc.LTM Jun 2026$2.72K -71.9%-13.9%—
Peer median (excluding HLS.TO) $4.56M-17.5%-3.5%6.2%

Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.01M61.47M63.07M56.62M56.47M
Cost of Revenue3.97M4.98M7.62M9M32.46M
Gross Profit56.04M56.49M55.45M47.62M24.01M
Gross Margin93.4%91.9%87.9%84.1%42.5%
Research & Development00000
Selling, General & Admin32.06M35.58M28.29M26.93M22M
Operating Expenses62.32M69.98M55.45M55.31M28.19M
Depreciation & Amortization30.26M34.4M31.94M22.72M22.2M
EBITDA25.41M18M12.88M17.22M18.02M
EBITDA Margin42.3%29.3%20.4%30.4%31.9%
Operating Income(6.24M)(13.44M)(10.35M)(7.69M)(4.18M)
Operating Margin-10.4%-21.9%-16.4%-13.6%-7.4%
Interest Income44K57K350K319K108.87K
Interest Expense6.96M7.32M8.75M10.08M7.22M
Other Income / Expenses(5.52M)(10.23M)(17.45M)(7.9M)(8.92M)
Income Before Tax(11.81M)(23.72M)(27.8M)(15.58M)(13.1M)
Pre-Tax Margin-19.7%-38.6%-44.1%-27.5%-23.2%
Income Tax Expense1.31M(124K)(272K)4.07M(452.79K)
Net Income(13.12M)(23.6M)(27.53M)(19.66M)(12.65M)
Net Margin-21.9%-38.4%-43.6%-34.7%-22.4%
EPS (Basic)(0.41)(0.73)(0.85)(0.62)(0.40)
EPS (Diluted)(0.41)(0.73)(0.85)(0.62)(0.40)
Weighted Avg Shares32.18M32.33M32.26M31.84M31.53M
Weighted Avg Shares (Diluted)32.18M32.43M32.26M31.84M31.53M

HLS Therapeutics Inc.

TSX:HLS.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.